Boiron Lawsuit Claims Company Deceptively Markets Homeopathic Products

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Boiron Homeopathic Drug Lawsuit Overview: 

• Who: Center for Inquiry (CFI) has filed a lawsuit against Boiron, Inc. 
• Why: CFI claims Boiron deceptively markets the ability of its homeopathic products to cure consumers’ health ailments. 
• Where: The lawsuit was filed in the Superior Court of the District of Columbia.

Homeopathic drugmaker Boiron deceptively markets its products to consumers by falsely claiming they will cure various health ailments, a new lawsuit alleges. 

In the lawsuit, the nonprofit group Center for Inquiry (CFI) claims Boiron deceives consumers about what their products are and the effectiveness they have in violation of the District of Columbia Consumer Protection Procedures Act.

CFI argues the products sold by Boiron consist of sugar pills and powders despite the company’s claims that they treat a variety of different health ailments and are marketed as having formulas that are scientific and evidence-based. 

“Through a carefully crafted scheme of misrepresentation, obfuscation, ambiguity, innuendo and falsities, Boiron offloads otherwise worthless products upon the unwitting, the ill-informed and the vulnerable,” the Boiron lawsuit states.

CFI says it purchased four of Boiron’s products over the past summer to test the company’s claims and examine their ingredients. 

Boiron categorizes its products by the illnesses they purport to cure, including joint and muscle pain, skin issues and motion sickness, among other things, according to the lawsuit. 

CFI argues that, despite this grouping, all of the homeopathic products contain the same ingredients with no difference between them. 

Boiron Deceives Consumers By Presenting Drugs As Legitimate, Lawsuit Alleges

By differentiating the products, CFI argues Boiron deceives consumers by pushing them to believe there is a “a legitimate, proven basis for its claims and promises.”

CFI claims further that Boiron deceives consumers with the labeling on its products, which gives the false impression that they are regulated by a governmental body. 

Boiron’s products are only regulated by the Homeopathic Pharmacopoeia Convention of the United States, which is self-described as non-governmental and nonprofit. 

Supporters of homeopathic treatments believe they can be used to cure individuals who are suffering from a certain type of harm despite those same treatments potentially causing that same harm in a healthy individual, according to the lawsuit.

CFI says that the idea of homeopathy is also centered around the belief that the more diluted a substance is the greater its ability to cure a health problem will be. 

In 2016, a second disbursement of settlement funds went out to eligible claimants following claims Boiron overstated the effectiveness of its homeopathic products. 

Have you taken a homeopathic drug manufactured and sold by Boiron? Let us know in the comments! 

The Center for Inquiry is represented in-house by Aaron D. Green and Nicholas J. Little. 

The Lenovo Sale Pricing Class Action Lawsuit is Center for Inquiry, Inc. v. Boiron, Inc. in the Superior Court of the District of Columbia.

Read About More Class Action Lawsuits & Class Action Settlements:

• Kern’s Nectar Class Action Alleges Juice Is Not Natural
• Teva Pharmaceuticals Recalls Acute Myeloid Leukemia Drug Over Particulate Matter Contamination
• Mylan Pharmaceuticals Recalls Batch Of Insulin Glargine Injection Product Over Missing Label Concerns
• Multiple Hand Sanitizer Brands Contaminated With Benzene, Warns Lab